Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.88 USD

86.88
215,820

+2.51 (2.97%)

Updated Jul 8, 2024 04:00 PM ET

After-Market: $86.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Glaxo's Shingles Candidate Gets Positive FDA Committee Vote

Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.

    Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable

    Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).

      Arpita Dutt headshot

      5 Top-Ranked Biotech Stocks to Buy Right Now

      If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

        Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth

        Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.

          Alnylam Shares Plunge on Patient Death, Dosing Suspended

          Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.

            Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?

            Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Ligand (LGND) Diabetes Candidate Positive in Phase II Study

              Ligand's (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks.

                Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%

                Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 120% on the day amid huge volumes.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data

                  Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.

                    Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label

                    The European Commission approves Amgen's (AMGN) marketing application for Mimpara's pediatric formulation to heal secondary hyperparathyroidism (HPT).

                      Top Ranked Momentum Stocks to Buy for August 30th

                      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 30th:

                        3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock

                        Momentum Stock Investors Will Love Ligand Pharmaceuticals (LGND) seeing its favorable price performance both in short and long term.

                          Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.

                          Vertex Pharmaceuticals' (VRTX) regulatory applications for tezacaftor/ivacaftor (Kalydeco) combination have been accepted by the FDA and EMA for review.

                            Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%

                            Myovant Sciences Ltd. (MYOV) was a big mover last session, as the company saw its shares rise over 16% on the day.

                              Can Ligand's Captisol Deals Boost Growth in the Long Run?

                              Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same.

                                Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised

                                Ligand's (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.

                                  Can Ligand (LGND) Pull a Surprise This Earnings Season?

                                  Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.

                                    Ligand Signs Agreement with Amgen, Grants Rights to Captisol

                                    Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330

                                      Ligand Gets Milestone Payment on Partner Drug FDA Approval

                                      Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the FDA.

                                        Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?

                                        Ligand Pharmaceuticals (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Arpita Dutt headshot

                                          Key FDA Events to Watch Out for in Jun 2017

                                          Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

                                            Ligand (LGND) Signs Licensing Deal with xCella Biosciences

                                            Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.

                                              Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates

                                              Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.

                                                Can Ligand (LGND) Spring a Surprise this Earnings Season?

                                                Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                                                  New Strong Sell Stocks for March 7th

                                                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: